Haematologic Malignancies
Galapagos focuses on relapsed or refractory blood cancers, with studies in multiple myeloma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and B-cell non-Hodgkin lymphoma. The portfolio includes CAR T-cell therapy and anti-CD19 or anti-BCMA approaches aimed at difficult-to-treat malignant B-cell disorders.
- Relapsed/refractory multiple myeloma
- Chronic lymphocytic leukemia and small lymphocytic lymphoma
- B-cell non-Hodgkin lymphoma
- CAR T-cell therapies
These oncology programs span multiple active sites across several countries, reflecting a strong interest in advanced cellular immunotherapy for resistant haematologic disease.
Autoimmune and Inflammatory Disease
The sponsor also supports research in systemic lupus erythematosus, including treatment-refractory active SLE, and in dermatomyositis. These studies address autoimmune disease activity, symptom burden, and systemic inflammation in conditions with limited therapeutic options.
- Systemic lupus erythematosus
- Treatment-refractory active SLE
- Dermatomyositis
- Inflammatory and autoimmune diseases
Within this area, Galapagos is engaged in both cutaneous and systemic immune-mediated disorders, extending its research beyond oncology into chronic autoimmune pathology.
Cell Therapy Development
A major area of interest is the development of autologous CAR T-cell products manufactured for use in oncology and followed through long-term safety monitoring. The research landscape includes treatment programs built around point-of-care manufactured cell therapy and persistent evaluation of post-infusion outcomes.
- Autologous CAR T-cell products
- Point-of-care manufactured cell therapy
- Long-term safety follow-up
- Post-infusion monitoring
These activities show sustained involvement in next-generation cellular medicines for haematologic cancer.
Immunology and Translational Medicine
Galapagos’ trial portfolio links immunology with translational research in immune-driven disease, including studies that examine disease activity, efficacy, and safety in immune-mediated conditions. The focus includes pathways relevant to both malignant and non-malignant immune dysfunction.
- Immunology
- Immune-mediated conditions
- Disease activity assessment
- Translational therapeutic development
This area connects the company’s oncology and autoimmune programs through a shared emphasis on immune system modulation.
